id: statin_prescription_access_to_mortality_mash_cirrhosis
name: Statin Prescription Access â†’ Mortality in MASH Cirrhosis Patients
from_node:
  node_id: statin_prescription_access
  node_name: Statin Prescription Access
to_node:
  node_id: mortality_mash_cirrhosis
  node_name: Mortality in MASH Cirrhosis Patients
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Statin therapy is historically underutilized in patients with chronic liver
  disease, creating a treatment gap'
- 'Step 2: Active statin prescription at time of liver transplant evaluation provides
  pharmacological benefit in metabolic dysfunction-associated steatohepatitis'
- 'Step 3: Statins reduce inflammation and fibrosis progression in MASH cirrhosis
  through lipid-lowering and pleiotropic effects'
- 'Step 4: Reduced disease progression and cardiovascular complications lower mortality
  risk in decompensated MASH patients'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Katherine M Cooper et al. 2025. "Statin Therapy is Associated
    With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic
    Dysfunction-associated Steatohepatitis.." *Journal of clinical and experimental
    hepatology*. https://doi.org/10.1016/j.jceh.2024.102427
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.379470'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: cirrhosis_etiology
  direction: strengthens
  strength: strong
  description: Statin benefit specific to MASH cirrhosis (mortality 16% vs 35%) but
    associated with increased mortality in non-MASH cirrhosis, particularly high-MELD-Na
    patients
- name: disease_severity_meld_na
  direction: weakens
  strength: strong
  description: High MELD-Na scores associated with increased mortality risk with statin
    use in non-MASH cirrhosis patients
- name: metabolic_comorbidity_profile
  direction: strengthens
  strength: moderate
  description: Statin users were older, had higher BMI, and more coronary artery disease;
    benefit appears strongest in metabolic dysfunction context
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/statin_prescription_access_to_mortality_mash_cirrhosis.yaml
_category: healthcare_access
